Compare EchoStar Corporation Common Stock (ECHO) vs Organon & Co. Common Stock (OGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
EchoStar Corporation Common Stock vs Organon & Co. Common Stock — how do they compare? EchoStar Corporation Common Stock trades at $87.13 (market cap $26.63B), while Organon & Co. Common Stock trades at $13.58 (market cap $3.62B). The key difference: EchoStar Corporation Common Stock is far larger — about 7.4× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while EchoStar Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold EchoStar Corporation Common Stock for 6 Days and Organon & Co. Common Stock for 0 Days on average.
| ECHO | OGN | |
|---|---|---|
Market Cap | $26.63B | $3.62B |
Volume | 2,918,300 | 2,892,999 |
Sector | Media | Health |
52-Week High | $141.80 | $13.81 |
52-Week Low | $66.93 | $5.70 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $43.68B | $11.04B |
Dividend Yield | — | 0.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ECHO trades at $91.56, down 3.72% over 24 hours, with a neutral technical signal and mixed earnings history including a significant Q2 2026 beat. The company reported a net loss of $14.50 billion in 2025, with negative cash flows, though revenue remains substantial at $15.00 billion. Recent news highlights institutional investments and a strategic partnership with United Airlines for in-flight streaming.
Analyst consensus is strongly bullish with a $134.00 price target, but high risks stem from persistent losses, negative cash flow, and the Hughes unit's bankruptcy. The stock's appeal hinges on turnaround execution and debt reduction efforts outweighing fundamental weaknesses.
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About EchoStar Corporation Common Stock
EchoStar provides satellite communications and connectivity services. Its businesses support broadband, enterprise, government, and consumer communications needs.
Read more on ECHO →About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →
